David Brachman
Papers
1
Total Citations
128
H-Index
1
About
David Brachman is a leading radiation oncologist whose research centers on stereotactic body radiation therapy (SBRT) for prostate cancer, with a focus on optimizing treatment efficacy while minimizing toxicity. His major contribution is demonstrating that extreme hypofractionation—delivering high-dose radiation in fewer sessions—is both safe and effective across multiple clinical centers. His landmark 2018 multicenter trial, cited over 128 times, provided pivotal evidence that dose-escalated SBRT for low- and intermediate-risk prostate cancer yields excellent survival outcomes with manageable side effects, challenging conventional fractionation schedules. This work has helped establish SBRT as a standard option for patients, reducing treatment from weeks to just days. Brachman’s research bridges radiobiology and clinical practice, showing that prostate cancer’s unique biology favors this approach. His findings have shaped national guidelines and inspired further studies on hypofractionation, making him a key figure in advancing non-invasive cancer care. For students and researchers, his work exemplifies how rigorous multicenter trials can translate biological insights into tangible patient benefits.
Research Focus
Key Achievements
Top Papers
- 1